Stock analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.
Syros Pharmaceuticals Price Performance
Shares of NASDAQ:SYRS opened at $0.03 on Wednesday. Syros Pharmaceuticals has a 12 month low of $0.02 and a 12 month high of $6.93. The firm has a market capitalization of $804,960.00, a price-to-earnings ratio of -0.01 and a beta of 1.31. The business’s 50 day simple moving average is $0.06 and its 200-day simple moving average is $0.47.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Syros Pharmaceuticals stock. Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Free Report) by 87.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 298,575 shares of the company’s stock after acquiring an additional 139,400 shares during the quarter. Exome Asset Management LLC owned approximately 1.11% of Syros Pharmaceuticals worth $642,000 as of its most recent filing with the Securities and Exchange Commission. 91.47% of the stock is currently owned by hedge funds and other institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Featured Stories
- Five stocks we like better than Syros Pharmaceuticals
- 3 Stocks to Consider Buying in October
- The Most Inspiring Small Businesses of 2025 [Survey]
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Microsoft Crushes Earnings, What’s Next for MSFT Stock?
- What is a support level?
- McDonald’s Insiders Sell Shares! Investors Should Do the Opposite
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
